Dosage calculator

GLP-1 Vial Transition Calculator

When your compounding pharmacy changes the vial concentration, the number of syringe units you need to draw changes — even though your milligram dose stays the same. This is the #1 compounded GLP-1 dosing error. This calculator shows you the exact new unit count and flags dangerous transitions.

mg

Your dose stays the same

1 mg

Old vial (2.5 mg/mL)

4units

= 0.400 mL drawn

New vial (5 mg/mL)

2units

= 0.200 mL drawn

Visual comparison

Old
40 u
New
20 u

Change

-2 units(-50%)

Concentration went from 2.5 to 5 mg/mL (2.0× more concentrated)

Check your vial label every time. The concentration is printed on the vial. If it is different from your previous vial, you must recalculate your syringe units before drawing.

Why concentration transitions are dangerous

The single most common dosing error in compounded GLP-1 therapy happens when the vial concentration changes and the patient does not adjust their syringe units. Because the formula is:

units = (dose in mg × 100) ÷ concentration in mg/mL

...a higher concentration means fewer units for the same mg dose. If the patient keeps drawing the old number of units from a higher-concentration vial, they will inject a higher mg dose — potentially double or more [1].

Example: semaglutide 2.5 → 5 mg/mL

A patient on 1.0 mg/week semaglutide was drawing 40 units from a 2.5 mg/mL vial. The pharmacy switches to a 5 mg/mL vial. If the patient keeps drawing 40 units:

(40 × 5) ÷ 100 = 2.0 mg — double the intended dose.

The correct new reading is:

(1.0 × 100) ÷ 5 = 20 units — half the old reading.

This calculator does that math for you and warns you when the change is large enough to be high-risk (more than 2× change) or when the new unit count exceeds the syringe capacity (100 units for a standard U-100 insulin syringe) [1].

Common concentration transitions

  • Semaglutide 2.5 → 5 mg/mL: Patient was on a low-concentration vial and the pharmacy switches to a more concentrated formulation. Units are halved.
  • Semaglutide 5 → 10 mg/mL: High-dose patients (1.7-2.4 mg) on 5 mg/mL sometimes get switched to 10 mg/mL to reduce injection volume. Units are halved.
  • Tirzepatide 10 → 20 mg/mL: Higher-dose tirzepatide patients (10-15 mg) may switch to 20 mg/mL to keep the syringe reading under 100 units. Units are halved.
  • Any concentration decrease: If the new concentration is lower than the old one, the patient must draw more units. If the new reading exceeds 100 units, they will need to split into two draws.

Important safety disclaimer

This tool performs arithmetic only and does not provide medical advice. Every time you receive a new vial, verify the concentration on the label before drawing any dose. If the concentration is different from your previous vial, recalculate your units using this tool and confirm with your prescriber or compounding pharmacy before injecting.

Related tools and research

References

  1. 1.Becton, Dickinson and Company (BD). BD Ultra-Fine Insulin Syringes — Product Specifications and U-100 Standard. BD Diabetes Care Product Documentation. 2024. https://www.bd.com/en-us/products/diabetes/diabetes-injection/insulin-syringes
  2. 2.Novo Nordisk Inc. WEGOVY (semaglutide) injection — US Prescribing Information. FDA Approved Labeling. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s026lbl.pdf
  3. 3.Novo Nordisk Inc. OZEMPIC (semaglutide) injection — US Prescribing Information. FDA Approved Labeling. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035,209637s037lbl.pdf
  4. 4.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information. FDA Approved Labeling. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf
  5. 5.Eli Lilly and Company. MOUNJARO (tirzepatide) injection — US Prescribing Information. FDA Approved Labeling. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s039lbl.pdf
  6. 6.U.S. Food and Drug Administration. Compounded Drug Products — 503A and 503B Outsourcing Facility Information for Patients. FDA Drug Compounding Resources. 2024. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers